SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegel R, Xu J et al. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277300
  • 2
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 76581
  • 3
    Babjuk M, Oosterlinck W, Sylvester R et al. European Association of Urology. Guidelines on TaT1 (Non-muscle invasive) Bladder Cancer. Eur Urol 2008; 54: 30314
  • 4
    Phull JS, Jefferies ER, Bates TS et al. Modern transurethral resection in the management of superficial bladder tumours. Br J Med Surg Urol 2011; 4: 91100
  • 5
    Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 52331
  • 6
    Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 196470
  • 7
    Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist! Urol Int 2005; 74: 97101
  • 8
    Shah JB, Kamat AM. Fluorescence cystoscopy for nonmuscle invasive bladder cancer: is the honeymoon over for the blue light special? Cancer 2011; 117: 8823
  • 9
    Riedl CR, Daniltchenko D, Koenig F et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001; 165: 11213
  • 10
    Geavlete B, Jecu M, Multescu R et al. HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer–re-TURBT recurrence rates in a prospective, randomized study. Urology 2010; 76: 6649
  • 11
    Stenzl A, Penkoff H, Dajc-Sommerer E et al. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer 2011; 117: 93847
  • 12
    Burger M, Stief CG, Zaak D et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology 2009; 74: 12826
  • 13
    Higgins JPT, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration. 2011. Available at: http://www.cochrane-handbook.org. Accessed May 2011
  • 14
    Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
  • 15
    Filbeck T, Pichlmeier U, Knuechel R et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002; 168: 6771
  • 16
    Kriegmair M, Zaak D, Rothenberger KH et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002; 168: 4758
  • 17
    Babjuk M, Soukup V, Petrík R et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005; 96: 798802
  • 18
    Daniltchenko DI, Riedl CR, Sachs MD et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005; 174: 212933
  • 19
    Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007; 69: 6759
  • 20
    Denzinger S, Wieland WF, Otto W et al. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 2008; 101: 5669
  • 21
    Stenzl A, Burger M, Fradet Y et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010; 184: 190713
  • 22
    Schumacher MC, Holmäng S, Davidsson T et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 2010; 57: 2939
  • 23
    Hermann GG, Mogensen K, Carlsson S et al. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011; 108: E297303
  • 24
    Drăgoescu O, Tomescu P, Pănuş A et al. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid. Rom J Morphol Embryol 2011; 52: 1237
  • 25
    Kausch I, Sommerauer M, Montorsi F et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010; 57: 595606
  • 26
    Kriegmair M, Baumgartner R, Knüchel R et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155: 10510